Insider trading

Period: 120 months Stock: GNLX Role: Other officers × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

51 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

51 decisions over 120 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

51 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

51 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
51 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
51 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

51 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
31 Aug 2026
Cappello Joseph Chief Technical Officer
Sold at will
$28.11K 10,257 at 2.74
3.1%
Not planned
31 Aug 2026
Yu Yong Chief Scientific Officer
Sold at will
$26.66K 9,683 at 2.75
3.6%
Not planned
4 Aug 2026
Cappello Joseph Chief Technical Officer
Sold at will
$1.92K 653 at 2.95
0.2%
Not planned
4 Aug 2026
Yu Yong Chief Scientific Officer
Sold at will
$1.92K 653 at 2.94
0.2%
Not planned
3 Jun 2026
Smalling Ralph Head of Regulatory
Sold at will
$562.56 192 at 2.93
0.3%
Not planned
11 May 2026
Cappello Joseph Chief Technical Officer
Sold at will
$1.80K 605 at 2.97
0.4%
Not planned
11 May 2026
Yu Yong Chief Scientific Officer
Sold at will
$1.80K 605 at 2.97
0.4%
Not planned
11 May 2026
Smalling Ralph Head of Regulatory
Sold at will
$804.49 270 at 2.98
0.4%
Not planned
25 Mar 2026
Smalling Ralph Head of Regulatory
Sold at will
$602.40 240 at 2.51
0.4%
Not planned
24 Mar 2026
Yu Yong SVP, Clinical Development
Sold at will
$2.19K 906 at 2.42
0.6%
Not planned
24 Mar 2026
Cappello Joseph Chief Technical Officer
Sold at will
$2.19K 906 at 2.42
0.6%
Not planned
24 Mar 2026
Smalling Ralph Head of Regulatory
Sold at will
$834.90 345 at 2.42
0.5%
Not planned
5 Dec 2025
Smalling Ralph Head of Regulatory
Sold at will
$773.85 165 at 4.69
0.2%
Not planned
17 Nov 2025
Cappello Joseph Chief Technical Officer
Sold at will
$5.22K 973 at 5.37
0.6%
Not planned
17 Nov 2025
Yu Yong SVP, Clinical Development
Sold at will
$5.22K 973 at 5.37
0.7%
Not planned
17 Nov 2025
Smalling Ralph Head of Regulatory
Sold at will
$1.84K 343 at 5.37
0.5%
Not planned
3 Sep 2025
Smalling Ralph Head of Regulatory
Sold at will
$1.95K 580 at 3.36
0.8%
Not planned
21 Aug 2025
Yu Yong SVP, Clinical Development
Sold at will
$10.81K 3,219 at 3.36
2.1%
Not planned
21 Aug 2025
Cappello Joseph Chief Technical Officer
Sold at will 2×
$9.14K 2,733 at 3.34
1.7%
Not planned
21 Aug 2025
Smalling Ralph Head of Regulatory
Sold at will
$4.18K 1,244 at 3.36
1.8%
Not planned
12 May 2025
Yu Yong VP, Clinical Trial Operations
Sold at will
$16.29K 5,579 at 2.92
10.5%
Not planned
12 May 2025
Cappello Joseph VP, Pharmaceutical Development
Sold at will
$13.83K 4,737 at 2.92
8.3%
Not planned
12 May 2025
Ryder Sean General Counsel
Sold at will
$13.07K 4,475 at 2.92
8.6%
Not planned
12 May 2025
Smalling Ralph Head of Regulatory
Sold at will
$3.68K 1,259 at 2.92
3.5%
Not planned
16 Dec 2024
Cappello Joseph VP, Pharmaceutical Development
Sold at will
$14.74K 6,300 at 2.34
30.1%
Not planned
16 Dec 2024
Smalling Ralph Head of Regulatory
Sold at will
$5.87K 2,510 at 2.34
13.3%
Not planned
24 Jun 2024
Yu Yong VP, Clinical Trial Operations
Sold at will
$14.52K 6,849 at 2.12
38.7%
Not planned
24 Jun 2024
Ryder Sean General Counsel
Sold at will
$11.65K 5,496 at 2.12
22.1%
Not planned
24 Jun 2024
Jewett Caroline Head of Quality
Sold at will
$10.52K 4,961 at 2.12
23.5%
Not planned
29 May 2024
Ryder Sean General Counsel
Bought
no price 10,000 shares
×17
First buy on file
29 May 2024
Smalling Ralph Head of Regulatory
Bought
no price 1,250 shares
10.4%
First buy on file
29 May 2024
Yu Yong VP, Clinical Trial Operations
Bought
no price 2,500 shares
opened
First buy on file
15 Dec 2023
Yu Yong VP, Clinical Trial Operations
Sold at will 2×
$428.18K 32,535 at 13.16
100%
Sold half or more
7 Dec 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$436.00K 36,800 at 11.85
53.1%
Sold half or more
21 Nov 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$191.56K 18,665 at 10.26
21.2%
Not planned
20 Nov 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$164.26K 14,594 at 11.26
14.2%
Not planned
17 Nov 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$46.17K 3,541 at 13.04
3.3%
Not planned
24 Oct 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$99.35K 5,200 at 19.11
4.7%
Not planned
10 Oct 2023
Yu Yong VP, Clinical Trial Operations
Sold at will 2×
$114.46K 5,200 at 22.01
4.7%
Not planned
26 Sep 2023
Yu Yong VP, Clinical Trial Operations
Sold at will 3×
$122.53K 5,200 at 23.56
4.7%
Not planned
20 Sep 2023
Ryder Sean General Counsel
Sold at will
$300.00K 10,000 at 30.00
94.6%
Sold half or more
20 Sep 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$167.79K 6,000 at 27.96
5.4%
Not planned
15 Sep 2023
Yu Yong VP, Clinical Trial Operations
Sold at will 2×
$227.63K 10,400 at 21.89
8.9%
Not planned
13 Sep 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$629.93K 29,800 at 21.14
21.9%
Not planned
30 Aug 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$489.06K 19,800 at 24.70
12.7%
Not planned
18 Aug 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$77.48K 3,265 at 23.73
2.1%
Not planned
18 Aug 2023
Cappello Joseph VP, Pharmaceutical Development
Sold at will
$77.48K 3,265 at 23.73
36.3%
Not planned
18 Aug 2023
Smalling Ralph Head of Regulatory
Sold at will
$22.19K 935 at 23.73
31.2%
Not planned
18 Aug 2023
Jewett Caroline Head of Quality
Sold at will
$12.22K 515 at 23.73
31.2%
Not planned
18 Aug 2023
Ryder Sean General Counsel
Sold at will
$7.78K 328 at 23.73
36.4%
Not planned
Showing 1–50 of 51. Page 1 of 2 Older →